After a volatile start to the year, BB Biotech achieved an impressive turnaround. The company posted a net profit of 448 million Swiss francs in the third quarter, compared with a loss of 157 million francs in the same period last year. The net asset value (NAV) rose by 24 percent, and the share price climbed 20 percent – both figures well above the benchmark Nasdaq Biotech Index, which gained 15.6 percent.

According to Friday’s release, management attributed the strong performance to a combination of focused portfolio management, renewed market momentum, and increased M&A activity across the biotech sector.

Rate Cuts and Renewed Risk Appetite

A more favorable macroeconomic environment supported the recovery. The US Federal Reserve’s interest rate cut in September 2025 and easing inflation reignited investors’ appetite for risk.

Capital-intensive innovation – particularly in RNA and biologics research – has received new impetus as a result.

Innovation Power and Disciplined Portfolio Management

The investment team maintained its disciplined focus, reducing the number of holdings from 23 to 21 while reinvesting funds in high-growth companies, including Revolution Medicines, Akero Therapeutics, and Scholar Rock.

New positions, including Avidity Biosciences, strengthened BB Biotech’s focus on RNA-based therapies – a field with high unmet medical need and long-term potential.

At the same time, the company sold its stakes in Moderna, Black Diamond Therapeutics, and Blueprint Medicines to free up capital for more attractive opportunities.

M&A Wave Signals Confidence in Innovation

The biotech market is experiencing a wave of strategic acquisitions. Industry giants such as Pfizer, Roche, Genmab, and Merck targeted innovative firms in 2025.

The announced acquisition of Akero Therapeutics by Novo Nordisk further underscores the attractiveness of the segment.

With its innovation-driven portfolio, BB Biotech considers itself ideally positioned to benefit from this consolidation phase.

Inclusion in the SPI ESG Index

Another highlight: BB Biotech’s inclusion in the SPI ESG Index – a move that underscores the company’s commitment to sustainable and responsible investing.

The combination of scientific excellence, financial discipline, and ESG focus positions BB Biotech as a leader among Switzerland’s listed investment firms.

Positive Outlook for 2026

With a solid liquidity base, an expanded US research team, and attractive market valuations, BB Biotech looks ahead to 2026 with confidence.

Several portfolio companies – including Agios and Incyte – are expected to report clinical progress in fields such as neurology, cardiology, and metabolic diseases.

The takeaway from Switzerland’s biotech investment specialist is clear: innovation, stability, and capital discipline increasingly go hand in hand – and BB Biotech is well positioned to benefit from the next phase of the sector’s recovery.